Development and validation of a novel risk score for the detection of insignificant prostate cancer in unscreened patient cohorts.

ABSTRACT:

Background

Active surveillance is recommended for insignificant prostate cancer (PCa). Tools exist to identify suitable candidates using clinical variables. We aimed to develop and validate a novel risk score (NRS) predicting which patients are harbouring insignificant PCa.

Methods

We used prospectively collected data from 8040 consecutive unscreened patients who underwent radical prostatectomy between 2006 and 2016. Of these, data from 2799 patients with Gleason 3 + 3 on biopsy were used to develop a multivariate model predicting the presence of insignificant PC at radical prostatectomy (ERSPC updated definition³: Gleason 3 + 3 only, index tumour volume < 1.3 cm³ and total tumour volume < 2.5 cm³). This was used to develop a novel risk score

SUBMITTER: Dutto L 

PROVIDER: S-EPMC6288120 | biostudies-literature | 2018 Dec

REPOSITORIES: biostudies-literature